The inhibitory effects of GB88 or SBTI on PAR2 activation which is induced by nTyr p3, by proteases present in mite allergens, suggest that PAR2 represents an attractive therapeutic target for allergen-induced allergic diseases. This evidence concerns the gene F2RL1 and allergic disease.